Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy

Blood Adv. 2020 Oct 13;4(19):4869-4872. doi: 10.1182/bloodadvances.2020002292.

Authors

Victor A Chow^{1

2}, Ajay K Gopal^{1

2}, Jordan Gauthier^{1

2}, Yolanda D Tseng^{1

3}, Cameron J Turtle^{1

2}, David G Maloney^{1

2}, Mazyar Shadman^{1

2}

Affiliations

¹ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and.
² Medical Oncology Division, Department of Medicine and.
³ Department of Radiation Oncology, University of Washington, Seattle, WA.

Abstract

No meaningful responses were observed when axicabtagene ciloleucel was used for progression after a different CD19-directed CAR T cell.
Further research is needed to understand how to sequence cell-based therapies for relapsed/refractory large B-cell lymphomas.

MeSH terms

Antigens, CD19 / therapeutic use
Biological Products
Humans
Immunotherapy, Adoptive*
Lymphoma, Large B-Cell, Diffuse*

Substances

Antigens, CD19
Biological Products
axicabtagene ciloleucel